Enhancing the dissolution of phenylbutazone using Syloid® based mesoporous silicas for oral equine applications
Three mesoporous silica excipients (Syloid® silicas AL-1 FP, XDP 3050 and XDP 3150) were formulated with a model drug known for its poor aqueous solubility, namely phenylbutazone, in an attempt to enhance the extent and rate of drug dissolution. Although other forms of mesoporous silica have been in...
Guardat en:
| Autors principals: | , , , , , , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Elsevier
2018-06-01
|
| Col·lecció: | Journal of Pharmaceutical Analysis |
| Accés en línia: | http://www.sciencedirect.com/science/article/pii/S2095177918300042 |
| Etiquetes: |
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|